Mission Wealth Management’s Verona Pharma VRNA Stock Holding History

Mission Wealth Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,500	Closed	-$540K	–	712
2025 Q1	$540K	Buy	+8,500	New	+$508K	0.01%	433

Other funds holding VRNA

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Mission Wealth Management's VRNA Position: Q2 2025 in Review

Mission Wealth Management sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 8,500 shares — an estimated $540K sold.

Mission Wealth Management first reported a position in VRNA in Q1 2025 and held it in 1 quarter. The position peaked at $540K in Q1 2025. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

Mission Wealth Management reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
Mission Wealth Management sold 8,500 Verona Pharma shares in Q2 2025, an estimated $540K.
Mission Wealth Management first reported a position in Verona Pharma in Q1 2025 and held it in 1 quarter.
Mission Wealth Management's Verona Pharma position peaked at $540K in Q1 2025.
292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on Mission Wealth Management's 13F filing for Q2 2025, filed 5 Aug 2025.